Tobacco mosaic virus for the targeted delivery of drugs to cells expressing prostate-specific membrane antigen.
Journal
RSC advances
ISSN: 2046-2069
Titre abrégé: RSC Adv
Pays: England
ID NLM: 101581657
Informations de publication
Date de publication:
06 Jun 2021
06 Jun 2021
Historique:
entrez:
28
6
2021
pubmed:
29
6
2021
medline:
29
6
2021
Statut:
epublish
Résumé
Prostate-specific membrane antigen (PSMA) is a membrane-bound protein that is preferentially expressed in the prostate gland and induced in many prostate cancers, making it an important target for new diagnostics and therapeutics. To improve the efficacy of nanoparticle formulations for the imaging and/or eradication of prostate cancer, we synthesized the PSMA-binding glutamic acid derivative DUPA and conjugated it to the external surface of tobacco mosaic virus (TMV) particles. DUPA-targeted TMV was subsequently loaded with the antineoplastic agent mitoxantrone (MTO) or conjugated internally with the fluorescent dye cyanine 5 (Cy5). We found that TMV particles could be efficiently decorated with DUPA and loaded with MTO or Cy5 while maintaining structural integrity. DUPA-targeted TMV particles were able to bind more efficiently to the surface of PSMA
Identifiants
pubmed: 34178308
doi: 10.1039/d1ra03166j
pii: d1ra03166j
pmc: PMC8180379
doi:
Types de publication
Journal Article
Langues
eng
Pagination
20101-20108Subventions
Organisme : NCI NIH HHS
ID : R01 CA202814
Pays : United States
Informations de copyright
This journal is © The Royal Society of Chemistry.
Déclaration de conflit d'intérêts
There are no conflicts to declare.
Références
Lancet. 2020 Apr 11;395(10231):1208-1216
pubmed: 32209449
Semin Nucl Med. 2019 Jul;49(4):302-312
pubmed: 31227053
Nanoscale. 2018 Aug 30;10(34):16307-16313
pubmed: 30129956
Hum Pathol. 2007 May;38(5):696-701
pubmed: 17320151
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
Adv Virus Res. 2018;102:149-176
pubmed: 30266172
Langmuir. 2011 Feb 15;27(4):1398-402
pubmed: 21090822
Biochem Pharmacol. 1985 Dec 15;34(24):4203-13
pubmed: 4074383
Nanoscale. 2013 May 7;5(9):3808-16
pubmed: 23519401
Nano Lett. 2014 Mar 12;14(3):1551-8
pubmed: 24499194
J Nucl Med. 2019 Oct;60(10):1394-1398
pubmed: 30850500
J Med Chem. 2009 Jan 22;52(2):347-57
pubmed: 19111054
Biochim Biophys Acta. 1998 Nov 26;1443(1-2):113-27
pubmed: 9838072
Methods Mol Biol. 2014;1108:173-85
pubmed: 24243249
J Nucl Med. 2020 Jun;61(6):857-865
pubmed: 31732676
J Am Chem Soc. 2005 Mar 23;127(11):3718-23
pubmed: 15771505
Front Pharmacol. 2015 Dec 01;6:286
pubmed: 26648870
J Control Release. 2019 Sep 10;309:244-264
pubmed: 31351927
Pharmaceutics. 2019 May 03;11(5):
pubmed: 31058814
J Hematol Oncol. 2020 Oct 28;13(1):144
pubmed: 33115529
Adv Drug Deliv Rev. 2020;156:214-235
pubmed: 32603813
ACS Nano. 2016 Apr 26;10(4):4119-26
pubmed: 26982250
Mol Nutr Food Res. 2009 Feb;53(2):171-84
pubmed: 19101947
Prostate. 2004 Feb 1;58(2):200-10
pubmed: 14716746
ACS Nano. 2017 Sep 26;11(9):9249-9258
pubmed: 28858475
Clin Cancer Res. 2012 Sep 15;18(18):4889-94
pubmed: 22829203
Int J Environ Res Public Health. 2016 Nov 25;13(12):
pubmed: 27898016
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593